EMAP

Program Information

Country:

Albania

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Ireland

Italy

Latvia

Lithuania

Malta

Netherlands

Norway

Poland

Portugal

Romania

Serbia

Slovakia

Slovenia

Spain

Sweden

Switzerland

United Kingdom

Disease:

Covid-19

Diphtheria tetanus (dT)

Diphtheria tetanus, pertusis (dTaP)

Diphtheria tetanus, pertusis, polio (dTaP-IPV)

Diphtheria tetanus, pertusis, polio, HiB (dTaP-IPV-Hib)

Diphtheria tetanus, pertusis, polio, HiB, HepB (dTaP-IPV-Hib-HepB)

Diphtheria tetanus, polio (dT-IPV)

Haemophilis influenzae Gp B

Haemophilis influenzae Gp B, Meninococcal Gp C (Hib-MenC)

Hepatitis A

Hepatitis B

Human papillomavirus (HPV)

Influenza

Measles, mumps, rubella +/- varicella (MMR +/- V)

Meninococcal Gp ACWY

Meninococcal Gp B

Meninococcal Gp C

Pertusis (aP)

Pneumococcal Disease

Polio (IPV)

Respiratory syncitial virus (RSV)

Rotavirus

Shingles

Tick-borne encephalitis (TBE)

Tuberculosis

Varicella

Population (in million):

Cohort details

Age Range:

Gender:

Type of cohorts:

Geographical distribution:

Risk factors:

Recommendation details

Vaccine:

Abrysvo

Arexvy

Avaxim

aP

BCG

Beyfortus

C2

Clesrovimab

Covid-19

dTaP

dTaP-IPV

dTaP-IPV-Hib

dTaP-IPV-Hib-HepB

dT

Diphtheria tetanus, polio (dT-IPV)

Engerix B

Flu

G4

G9

Havrix

HBVaxPro

Heplisav B

Hevac B

Hexacima

Hexyon

Hib

Hib-MenC

Infrarix Hexa

IPV

MenACWY

MenB

MenC

MMR II

PCV13

PCV15

PCV20

PCV21

PCV7

PPSV23

PreHevbri

Priorix

Priorix Tetra

Proquad

Rotarix

Rotateq

Shingrix

Synagis

TBE

Varitrix

Varivax

Vaqta

Vaxelis

Zostavax

Number of doses:

Ongoing Recommendation:

HTA Decision:

Recommendation body:

Type of Recommendation:

Public Funding

Public Funded:

Public Funding Source:

Funding level (%):

Delivery framework

Point of Vaccination:

Hospital

GP

Vx center

Specialist

Pharmacy

School

Pediatrician Office

OBGYN

Outpatient clinic

Procurement type:

Table View

Program Information				Cohort Details								Program Details														References
ID A unique identification number automatically allocated to each cohort / entry in the database.	Country	Region	Disease	Age Start The lowest age at which individuals are eligible to receive the first dose of a vaccine schedule.	Age End The highest age at which individuals are eligible to receive the last dose of a vaccine schedule	Gender	Type of Cohort Primary: Routine vaccination of individuals targeted to receive a specific vaccine schedule for the first time; Catch-up: Vaccination of individuals who missed primary vaccination; Booster: Vaccination of individuals targeted to receive additional doses of a vaccines schedule, after receiving the primary vaccination; At-risk: Groups of individuals with an increased likelihood of exposure or development of a disease. Typically including chronic disease; High-risk: Groups of individuals, a subset of at-risk groups, who are at a particularly high risk of severe outcomes and often require more urgent or specialized preventive measures. Typically including immunocompromise; Age-based: Vaccination of individuals defined only based on age;	Geographical Distribution The administrative-territorial public health authority issuing the recommendation	Risk Factors Factors which increase the risk of developing a disease or the severity of the disease	Size of Cohort	Point of Vaccination Type of institution where the vaccine is administered	Immunization Recommendation Body The type of institution which issued the vaccination recommendation	Type of Recommendation	Vaccines Recommended A vaccination schedule comprises one or more doses of vaccine, administered in a particular order and interval. Alternative vaccination schedules are available when two or more different vaccines (or combinations thereof) can be used interchangeably.	Number of Doses Recommended The number of doses of each vaccine in the recommended schedule	Starting Year of the Recommendation	Last Update of the Recommendation	Ongoing Recommendation Defines if a vaccination recommendation is current	Public Funded Reimbursement or funding from public sources (national or subnational)	HTA Decision Specifies whether a recommendation and/or funding was supported by an HTA typically submitted by the manufacturer of a given product	Public Funding Source The type of institution providing the funding of the recommended vaccination schedule	Public Funding Level The % of the cost of the vaccination scheme which is funded from public sources	Starting Year of Funding	Procurement Type The predominant method for procurement of publicly funded vaccine	References	Last update	Population

Edit Table
Add a program

Program Information

Country:

Disease:

Cohort Details

Age Start:

Age End:

Gender:

Type of Cohorts:

Geographical Distribution:

Risk Factors:

Point of Vaccination:

Size of Cohort:

Program Details

Immunization Recommendation Body:

Type of Recommendation:

Vaccines Recommended:

Number of Doses Recommended:

Starting Year of the Recommendation:

Last Update of the Recommendation:

Ongoing Recommendation:

Public Funded:

HTA Decision:

Public Funding Source:

Public Funding Level (%):

Starting Year of Funding:

Procurement Type:

References:

Action	ID A database entry should be defined for one cohort, which is recommended to be vaccinated with one or more vaccines and/or doses, all having the same type of funding. In case of broad and unspecific recommendations, define separate entries for each goup of vaccines having the same level of funding (ex. one entry for the cohort recommended for vaccination with the vaccines that lost the tender and one for the vaccine that won the tender)	Country	Region	Disease	Age Start Round down to the minimum recommended age in years. Newborns, 0 to 11 months old, have cohort age defined as 0-0 yo. Children over 11 months and under 36 months, have cohort age defined as 1-2 yo	Age End Round down to the maximum recommended age in years. Newborns, 0 to 11 months old, have cohort age defined as 0-0 yo. Children over 11 months and under 36 months, have cohort age defined as 1-2 yo Leave empty in case there is no upper limit to the age	Gender	Type of Cohort Primary: Routine vaccination of individuals targeted to receive a specific vaccine schedule for the first time Ex. children 3-12 months old recommended to be vaccinated with 3 doses of DTaP-IPV-Hib-HepB vaccine Catch-up: Ex. adolescents or adults not vaccinated against HPV in the primary cohort, 9-14 yo Booster: Ex. individual needing a dTap booster after a DTaP-IPV-Hib-HepB vaccine At-risk: Ex. pregnancy, age, partially immunizied with other vaccines, etc High-risk: Groups of individuals, a subset of at-risk groups, who are at a particularly high risk of severe outcomes and often require more urgent or specialized preventive measures. Typically including immunocompromise Age-based: Ex. population above 65 yo recommended to be vaccinated for IPD prevention without other risk factors	Geographical Distribution Ex. national vs regional institutions recommendation	Risk Factors List all risk factors specified for the respective cohort in the vaccination recommendation	Size of Cohort	Point of Vaccination	Immunization Recommendation Body	Type of Recommendation	Vaccines Recommended Ex. MMRV schedule for children recommended to receive 1 dose of MMRII at age 1 and a 2nd dose of Proquad at age 5 (MMR II & Proquad) Arrange vaccines from a recommended schedule in chronological order and connect using &. Add alternative vaccination schedules, when 2 or more vaccines are interchangeable and separate schedules using / () are grouping different schedules Create separate database entries for different vaccination schedules with different types of funding (Ex. in case of IDP primary cohort with a recommendation for PCV13 and PCV15 but funding through winner-takes-all tender, two separate entries should be created, one for PCV 13 and one for PCV15 with their respective funding status)	Number of Doses Recommended	Starting Year of the Recommendation	Last Update of the Recommendation	Ongoing Recommendation Avoid deleting database entries when recommendations have been changed or revoked. Select NO to mark a recommendation no longer valid	Public Funded	HTA Decision	Public Funding Source	Public Funding Level	Starting Year of Funding	Procurement Type	References